Shoamanesh, A., Field, T. S., Coutts, S. B., Sharma, M., Gladstone, D., Hart, R. G., … Healey, J. S. (2025). Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. LANCET NEUROLOGY, 24(1), 140–151. https://doi.org/10.1016/S1474-4422(24)00475-7

Shoamanesh, Ashkan, Thalia S. Field, Shelagh B. Coutts, Mukul Sharma, David Gladstone, Robert G. Hart, Giuseppe Boriani, et al. “Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.” LANCET NEUROLOGY 24, no. 1 (2025): 140–51. https://doi.org/10.1016/S1474-4422(24)00475-7.

Shoamanesh A, Field TS, Coutts SB, Sharma M, Gladstone D, Hart RG, et al. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. LANCET NEUROLOGY. 2025;24(1):140–51.

Shoamanesh, Ashkan, et al. “Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.” LANCET NEUROLOGY, vol. 24, no. 1, 2025, pp. 140–51. Wos-lite, doi:10.1016/S1474-4422(24)00475-7.

Shoamanesh A, Field TS, Coutts SB, Sharma M, Gladstone D, Hart RG, Boriani G, Wright DJ, Sticherling C, Birnie DH, Gold MR, Erath JW, Kutyifa V, Mian R, Benz AP, Granger CB, Mcintyre WF, Connolly SJ, Nielsen JC, Alings M, Rivard L, Lopes R, Healey JS. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. LANCET NEUROLOGY. 2025;24(1):140–151.